The First Affiliated Hospital of Xiamen University
Patients diagnosed with metastatic breast cancer will undergo 68Ga-MY6349 PET/CT imaging at baseline and after two cycles of Trop2-ADC therapy. Tumor uptake will be quantified using both maximum standardized uptake value (SUVmax) and mean SUV (SUVmean). Imaging changes will be correlated with treatment response to assess the utility of 68Ga-MY6349 PET/CT as a predictive biomarker.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
adult patients (aged 18 years or order)
histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging (e.g., MRI, CT), tumor markers, or pathology reports
presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee
You may not be if
Evidence of significantly impaired hepatic or renal function
Estimated life expectancy of less than 3 months
Clareo Health | PET/CT for Trop2 ADC Response Evaluation Cancers
